Hypomelanotic Disorder Clinical Trials

Find Hypomelanotic Disorder Clinical Trials Near You

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of EB06 Versus Placebo in Adults With Moderate to Severe Non-segmental Vitiligo

Status: Recruiting
Location: See all (4) locations...
Intervention Type: Biological, Other
Study Type: Interventional
Study Phase: Phase 2
SUMMARY

The purpose of this study is to evaluate the safety and efficacy of EB06 intravenous infusion (loading dose of 20mg/kg followed by a maintenance dose of 10mg/kg) compared with placebo in adults with moderate to severe non-segmental vitiligo.. Vitiligo is a chronic autoimmune skin disorder characterized by the loss of skin pigmentation due to the destruction of melanocytes. EB06 is a fully human monoclonal antibody that binds and neutralizes CXCL10, a chemokine implicated in the trafficking of anti-melanocytic T-cells to the epidermis and in inducing cell death. Elevated levels of CXCL10 have been associated with both the initiation of the disease and the maintenance of vitiligo lesions. The study will evaluate the safety, tolerability, and efficacy of EB06 in adults with moderate to severe non-segmental vitiligo.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Clinical diagnosis of non-segmental vitiligo with depigmented area including ≥ 0.5% BSA on the face, ≥ 0.5 F-VASI, ≥ 5% total BSA, and ≥ 4 T-VASI.

• Men and women ≥ 18 years of age at the time of consent.

• Subjects who agree to discontinue all agents used to treat vitiligo from screening through to Week 28. Over the counter preparations deemed acceptable by the investigator and camouflage makeups are permitted.

• Female subjects of childbearing potential and at risk for pregnancy: negative pregnancy test and agreement to use at least one method of effective contraception throughout the study and for at least 12 weeks after the last dose of assigned treatment.

• Male subjects with female partners of childbearing potential agree to use at least one method of effective contraception by yourself or your partner, as applicable, during study duration and for at least 12 weeks after the last dose of assigned treatment.

Locations
Other Locations
Canada
Vida Clinical Research
NOT_YET_RECRUITING
Edmonton
Guelph Dermatology Research
NOT_YET_RECRUITING
Guelph
Clear Skin Dermatology
NOT_YET_RECRUITING
Newmarket
FACET Dermatology
RECRUITING
Toronto
Time Frame
Start Date: 2026-09
Estimated Completion Date: 2027-12
Participants
Target number of participants: 80
Treatments
Placebo_comparator: Placebo
Experimental: EB06
Related Therapeutic Areas
Sponsors
Leads: Edesa Biotech Inc.
Collaborators: JSS Medical Research Inc.

This content was sourced from clinicaltrials.gov

Similar Clinical Trials